Specific financial terms of the transaction are confidential, however, both companies will share in resulting revenue.
“We are very excited about working with Zylera, as our patents are very complementary to their own R&D activities,” stated David Preston, chairman and CEO, Theragenex. “They are well down the road with several science-based pharmaceutical formulations that will benefit patients suffering from chronic diseases. We believe this technology licensing agreement accelerates the potential time to market of these product candidates.”
Theragenex is a life science and technology development company focused on acquiring patents and intellectual property addressing a wide range of therapeutic opportunities.